- Trials with a EudraCT protocol (72)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
72 result(s) found for: Pulmonary consolidation.
Displaying page 1 of 4.
EudraCT Number: 2018-000205-22 | Sponsor Protocol Number: CYAD-N2T-005 | Start Date*: 2018-06-04 |
Sponsor Name:Celyad Onclogy SA | ||
Full Title: An open-label, Phase I/II study to assess the safety and clinical activity of NKR-2 treatment administration after a non-myeloablative preconditioning chemotherapy in relapse/refractory acute myelo... | ||
Medical condition: NKR-2 has the potential to treat many distinct tumor-types. This trial will focus on Relapsed and/or refractory (r/r) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-000050-10 | Sponsor Protocol Number: FORMaT001 | Start Date*: 2023-01-02 | |||||||||||
Sponsor Name:University of Queensland | |||||||||||||
Full Title: Finding the Optimal Regimen for Mycobacterium abscessus Treatment | |||||||||||||
Medical condition: Mycobacterium abscessus pulmonary disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005881-17 | Sponsor Protocol Number: RIN-PF-303 | Start Date*: 2022-08-18 | |||||||||||
Sponsor Name:UNITED THERAPEUTICS CORPORATION | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis (TETON-2) | |||||||||||||
Medical condition: Idiopathic Pulmonary Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) DK (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002464-75 | Sponsor Protocol Number: 534 | Start Date*: 2022-12-06 | |||||||||||
Sponsor Name:Groupe Hospitalier Paris Saint-Joseph | |||||||||||||
Full Title: Glucocorticoids versus placebo for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: a randomized controlled trial | |||||||||||||
Medical condition: Acute exacerbation of idiopathic pulmonary fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002632-24 | Sponsor Protocol Number: P160915 | Start Date*: 2018-11-13 |
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | ||
Full Title: Therapeutic plasma exchange, rituximab and intravenous immunoglobulins (IVIg) for severe acute exacerbation of idiopathic pulmonary fibrosis admitted in ICU: an open, randomized, controlled trial | ||
Medical condition: severe acute exacerbation of idiopathic pulmonary fibrosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-001735-66 | Sponsor Protocol Number: NXL103/2001 | Start Date*: 2007-10-01 | |||||||||||
Sponsor Name:Novexel S. A. | |||||||||||||
Full Title: A double blind, multicentre, multinational, randomized, double dummy, three-arm parallel-group comparative study of the efficacy, safety and tolerance of oral NXL103 (500 mg twice daily) versus NXL... | |||||||||||||
Medical condition: Community-Acquired Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004782-24 | Sponsor Protocol Number: PRM-151-202 | Start Date*: 2016-03-01 | |||||||||||
Sponsor Name:Promedior, Inc. | |||||||||||||
Full Title: A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects with Idiopathic Pulmonary Fibrosis (IPF) | |||||||||||||
Medical condition: Idiopathic Pulmonary Fibrosis (IPF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) CZ (Completed) ES (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002619-10 | Sponsor Protocol Number: OP-634-001 | Start Date*: 2004-11-10 | |||||||||||
Sponsor Name:Oscient Pharmaceuticals | |||||||||||||
Full Title: A Phase IIIb, Randomized, Double-Blind, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Oral Gemifloxacin 320 mg Once Daily for 5 Days Versus Oral Gemifloxacin 320 mg Once Da... | |||||||||||||
Medical condition: Mild to moderate community acquired bacterial pneumonia. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) LT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002116-14 | Sponsor Protocol Number: CCTL019G2201J | Start Date*: 2018-10-22 | ||||||||||||||||
Sponsor Name:Novartis Pharma AG | ||||||||||||||||||
Full Title: A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive... | ||||||||||||||||||
Medical condition: Pediatric and young adult patients aged 1 to 25 years with first-line NCI high-risk (HR) B-cell acute lymphoblastic leukemia (B-ALL) who are in CR1 with minimal residual disease (MRD) positive (MR... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Trial now transitioned) ES (Temporarily Halted) DK (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Completed) FI (Completed) NL (Trial now transitioned) NO (Trial now transitioned) SE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005890-24 | Sponsor Protocol Number: HM05/7287 | Start Date*: 2007-11-02 | |||||||||||
Sponsor Name:Leeds Teaching Hospitals NHS Trust | |||||||||||||
Full Title: Myeloma X Relapse (Intensive) - A randomised controlled trial to determine the role of a second autologous stem cell transplant as consolidation therapy in patients with relapsed multiple myeloma f... | |||||||||||||
Medical condition: Relapsed myeloma previously treated with chemotherapy and autologous stem cell transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003109-28 | Sponsor Protocol Number: ICLA-20-PNE1 | Start Date*: 2007-09-28 | |||||||||||
Sponsor Name:Arpida AG | |||||||||||||
Full Title: Randomized, double-blind, multicenter study to evaluate efficacy and safety of intravenous iclaprim versus vancomycin in the treatment of hospital-acquired, ventilator-associated, or health-care-as... | |||||||||||||
Medical condition: Hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), or health-care-associated pneumonia (HCAP) suspected or confirmed to be due to Gram-positive pathogens. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) LV (Prematurely Ended) LT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002609-78 | Sponsor Protocol Number: ETOP4-12/CA184-310 | Start Date*: 2015-02-17 | |||||||||||
Sponsor Name:ETOP (European Thoracic Oncology Platform) | |||||||||||||
Full Title: A randomised open-label phase II trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after chemo-radiotherapy | |||||||||||||
Medical condition: limited-stage SCLC | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) FR (Completed) DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001170-32 | Sponsor Protocol Number: H3E-MC-JMIG | Start Date*: 2008-09-05 | ||||||||||||||||
Sponsor Name:Eli Lilly and Company limited | ||||||||||||||||||
Full Title: Protocol H3E-MC-JMIG Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytoto... | ||||||||||||||||||
Medical condition: patients with locally advanced, unresectable/inoperable, Stage III, nonsquamous NSCLC without malignant pleural/pericardial effusion | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: PT (Completed) HU (Completed) ES (Completed) NL (Completed) BE (Completed) FR (Completed) DE (Completed) GB (Completed) IE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-005135-26 | Sponsor Protocol Number: PM0259 CA304 J1 | Start Date*: 2005-05-02 |
Sponsor Name:Pierre Fabre Médicament | ||
Full Title: ORAL VINORELBINE AND CISPLATIN WITH CONCOMITANT RADIOTHERAPY FOLLOWED BY EITHER CONSOLIDATION THERAPY WITH ORAL VINORELBINE AND CISPLATIN PLUS BEST SUPPORTIVE CARE OR BEST SUPPORTIVE CARE ALONE IN ... | ||
Medical condition: Stage III Non small cell lung cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2005-000105-65 | Sponsor Protocol Number: 1 | Start Date*: 2006-08-30 |
Sponsor Name:Medical University of Vienna, Department of Internal Med. I, Division of Infectious Diseases | ||
Full Title: Comparative study of the efficacy and tolerance of intravenously administered azithromycin (1.5 g) given either as a single dose or over a 3 day period in patients with community-acquired pneumonia | ||
Medical condition: community aquired pneumonia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002107-17 | Sponsor Protocol Number: RG_11-152 | Start Date*: 2013-02-01 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours | |||||||||||||
Medical condition: Ewing's Sarcoma Family of Tumours | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Completed) CZ (Completed) IE (Completed) HU (Completed) NL (Completed) DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000627-40 | Sponsor Protocol Number: IA-DUET | Start Date*: 2020-12-28 | |||||||||||
Sponsor Name:Erasmus MC | |||||||||||||
Full Title: Azole-echinocandin combination therapy for invasive aspergillosis. A randomized pragmatic superiority trial (IA-DUET) | |||||||||||||
Medical condition: Invasive aspergillosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002867-13 | Sponsor Protocol Number: POP6135,HMR3647B/3005 | Start Date*: 2015-03-17 | |||||||||||
Sponsor Name:Sanofi-aventis | |||||||||||||
Full Title: Multinational, randomized, double blind, double dummy, pharmacokinetic study of telithromycin oral suspension (25 mg/kg once daily for 7-10 days), with secondary assessments of safety relative to a... | |||||||||||||
Medical condition: Community acquired pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000412-33 | Sponsor Protocol Number: 3074K6-2000-WW | Start Date*: 2008-09-17 | |||||||||||
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development | |||||||||||||
Full Title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF TIGECYCLINE VERSUS IMIPENEM/CILASTATIN FOR THE TREATMENT OF SUBJECTS WITH HOSPITAL-ACQUI... | |||||||||||||
Medical condition: Hospital-Acquired Pneumonia (HAP) including Ventilator-Associated Pneumonia (VAP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) LV (Completed) FR (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000827-13 | Sponsor Protocol Number: A5951001 | Start Date*: 2007-11-26 | |||||||||||
Sponsor Name:Pfizer Pharmaceutical Group | |||||||||||||
Full Title: LINEZOLID IN THE TREATMENT OF SUBJECTS WITH NOSOCOMIAL PNEUMONIA PROVEN TO BE DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS | |||||||||||||
Medical condition: MRSA Infection - Nosocomical Pneumenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) DE (Completed) ES (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
